A Preliminary Clinical Study on the Effects of Oral Hypoglycemic Agents on the Stress Hyperglycemic Ratio in Type 2 Diabetes Patients in the Absence of Serious Illness
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Stress hyperglycemia Ratio
研究概览
简要总结
A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications
详细描述
Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia.
Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥35 years
- •Diagnosis of Type 2 diabetes
- •Absence of serious illnesses
- •No evidence of trauma
排除标准
- •Overt complications of diabetes
- •Any participant used antibiotics for infectious diseases
- •Any participant used non-steroidal antiinflammatory drugs
- •Current or past history of mental diseases
- •Current hematological diseases
- •Pregnancy
- •Nursing mothers
研究组 & 干预措施
Sitagliptin/metformin
Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks
干预措施: Sitagliptin/metformin ( 50/500mg) Oral Tablet (Drug)
Empagliflozin/metformin
Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks
干预措施: Empagliflozin/metformin(10/500mg) Oral Tablet (Drug)
结局指标
主要结局
Stress hyperglycemia Ratio
时间窗: 10 week
The ratio of stress-to-on admission blood glucose was calculated
次要结局
- Hematological indices(10 week)
- Inflammatory markers(10 week)
研究者
Marwan Salih Mohamad Al-Nimer
Emeritus Professor
University of Diyala